Clarivate (CLVT) has just expanded agentic AI capabilities across its Cortellis portfolio to help life sciences R&D teams cut manual work, speed up discovery and support more informed portfolio decisions.

These new agentic AI features arrive after a tough stretch for Clarivate’s stock, with the latest 30 day share price return down 14.35% and the year to date share price return down 41.05%, while the 1 year total shareholder return has declined 52.49%. Recent events, including deeper quarterly net losses, goodwill impairments and CFO changes announced in late July 2026, help explain why sentiment has weakened even as Clarivate pushes further into AI driven products like Cortellis.

If Clarivate’s AI push has your attention, it can also be worth widening your search to other companies at the heart of AI infrastructure using our 57 AI infrastructure stocks.

Clarivate now trades at a steep discount to both analysts’ targets and some intrinsic value estimates after its sharp slide. Is this just the market overreacting to recent losses and impairments, or a fair reset for a still loss making business?

Most Popular Narrative: 23.6% Undervalued

Clarivate’s most followed valuation narrative places fair value at $2.50 per share, above the latest close at $1.91, which casts the recent slide in a different light.

Rapid expansion and adoption of AI-driven product innovation across all segments (including new AI-powered analytics in Web of Science, Derwent, and Cortellis) enhances product differentiation and workflow integration, driving higher pricing, customer retention, and potentially expanding gross margins.

Want to see what sits behind that AI focus? The narrative leans heavily on recurring revenue, margin lift and a future profit multiple that has to support the jump from current losses. Curious how those pieces are expected to fit together into that $2.50 fair value.

Result: Fair Value of $2.50 (UNDERVALUED)

However, Clarivate’s narrative can be knocked off course if higher education budgets tighten further or if free and low cost research data erodes subscription demand.

Next Steps

With Clarivate pulling in both concern and optimism, this is a good moment to look at the data yourself and act before sentiment shifts again. To see how the positives and negatives line up in one place, start with the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Clarivate?

If Clarivate has sharpened your focus on opportunities, do not stop here. Use the Simply Wall Street Screener to spot other stocks that could deserve a closer look.

• Target steady compounding by reviewing companies with reliable payouts through the 8 dividend fortresses.
• Hunt for potential mispricings by checking companies that screen as 49 high quality undervalued stocks.
• Prioritise resilience first by scanning companies in the 85 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.